BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 2892647)

  • 1. Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker.
    Gray RJ
    Chest; 1988 Feb; 93(2):398-403. PubMed ID: 2892647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
    Barbier GH; Shettigar UR; Appunn DO
    Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
    Angaran DM; Schultz NJ; Tschida VH
    Clin Pharm; 1986 Apr; 5(4):288-303. PubMed ID: 2871961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
    Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
    J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esmolol: a novel cardioselective, titratable, intravenous beta-blocker with ultrashort half-life.
    Covinsky JO
    Drug Intell Clin Pharm; 1987 Apr; 21(4):316-21. PubMed ID: 2882993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias.
    Gray RJ; Bateman TM; Czer LS; Conklin CM; Matloff JM
    J Am Coll Cardiol; 1985 Jun; 5(6):1451-6. PubMed ID: 2860148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.
    Turlapaty P; Laddu A; Murthy VS; Singh B; Lee R
    Am Heart J; 1987 Oct; 114(4 Pt 1):866-85. PubMed ID: 2889341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esmolol, the first ultra-short-acting intravenous beta blocker for use in critically ill patients.
    Blanski L; Lutz J; Laddu A
    Heart Lung; 1988 Jan; 17(1):80-9. PubMed ID: 3276651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
    Wiest D
    Clin Pharmacokinet; 1995 Mar; 28(3):190-202. PubMed ID: 7758250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics and therapeutic efficacy of esmolol.
    Wiest DB; Haney JS
    Clin Pharmacokinet; 2012 Jun; 51(6):347-56. PubMed ID: 22515557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esmolol: a unique beta adrenergic antagonist.
    Maree SM
    J Neurosci Nurs; 1990 Apr; 22(2):121-4. PubMed ID: 1970595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.
    Mooss AN; Hilleman DE; Mohiuddin SM; Hunter CB
    Ann Pharmacother; 1994 Jun; 28(6):701-3. PubMed ID: 7919552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group.
    Anderson S; Blanski L; Byrd RC; Das G; Engler R; Laddu A; Lee R; Rajfer S; Schroeder J; Steck JD
    Am Heart J; 1986 Jan; 111(1):42-8. PubMed ID: 2868645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esmolol: a short-acting titratable beta-blocker in acute myocardial ischemia.
    Viray R; Turlapaty P; Laddu A
    Int J Clin Pharmacol Ther Toxicol; 1988 Mar; 26(3):153-61. PubMed ID: 2900818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of intravenous esmolol for cardiac protection in non-cardiac surgery. A systematic review and meta-analysis.
    Ollila A; Vikatmaa L; Sund R; Pettilä V; Wilkman E
    Ann Med; 2019 Feb; 51(1):17-27. PubMed ID: 30346213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new dosing regimen for esmolol to treat supraventricular tachyarrhythmia in Chinese patients.
    Ko WJ; Chu SH
    J Am Coll Cardiol; 1994 Feb; 23(2):302-6. PubMed ID: 7905013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New ultra-short-acting beta-blockers: landiolol and esmolol--the effects on cardiovascular system].
    Mio Y
    Masui; 2006 Jul; 55(7):841-8. PubMed ID: 16856544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled beta-receptor blockade with esmolol and flestolol.
    Murthy VS; Frishman WH
    Pharmacotherapy; 1988; 8(3):168-82. PubMed ID: 2902602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular and antiarrhythmic effects of esmolol in children.
    Trippel DL; Wiest DB; Gillette PC
    J Pediatr; 1991 Jul; 119(1 Pt 1):142-7. PubMed ID: 1676729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esmolol and beta-adrenergic blockade.
    Wolman RL; Fiedler MA
    AANA J; 1991 Dec; 59(6):541-8. PubMed ID: 1686346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.